PDS Biotechnology Corporation (PDSB) 10-Year Financial Performance & Capital Metrics

PDSB • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutPDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.Show more

Revenue $0
EBITDA -$36M +15.6%
Net Income -$38M +12.4%
EPS (Diluted) -1.03 +25.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -166.65% -36.1%
ROIC -
Debt/Equity 1.15 +25.8%
Interest Coverage -7.77 +24.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 19 (bottom 19%)
✗Shares diluted 17.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM13.98%

EPS CAGR

10Y-

5Y-

3Y-

TTM28.45%

ROCE

10Y Avg-64.35%

5Y Avg-72.21%

3Y Avg-79.38%

Latest-98.12%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	53.12K	100.12K	182.92K	69.12K	98.41K	0	0	0	57.33K	59.79K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-53.12K	-100K	-183K	-69.12K	-98.41K	0	0	0	-57.33K	-59.79K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.88%	-0.83%	0.62%	-0.42%	1%	-	-	-	-0.04%
Operating Expenses+	26.5M	39.51M	51.97M	3.65M	15.41M	14.9M	21.44M	41.67M	43.05M	36.26M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	8.66M	14.69M	17.66M	14.29M	9.31M	6.98M	10.18M	12.24M	15.28M	13.7M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	17.84M	24.82M	34.31M	830.74K	6.1M	7.92M	11.25M	29.43M	27.76M	22.57M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	-163.46K	0	12.74B	0	0	0	0	1K	0
Operating Income+	-26.5M	-39.51M	-51.97M	-43.1M	-15.51M	-14.9M	-21.44M	-41.67M	-43.05M	-36.32M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-1.01%	-0.49%	-0.32%	0.17%	0.64%	0.04%	-0.44%	-0.94%	-0.03%	0.16%
EBITDA+	-26.45M	-39.41M	-51.78M	-43.03M	-15.41M	-14.89M	-21.43M	-41.67M	-42.99M	-36.26M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1.01%	-0.49%	-0.31%	0.17%	0.64%	0.03%	-0.44%	-0.94%	-0.03%	0.16%
D&A (Non-Cash Add-back)	53.12K	100.12K	182.92K	69.12K	98.41K	15.61K	5.36K	86	57.33K	59.79K
EBIT	-28.37M	-39.46M	-51.27M	-3.83M	-7.35M	-14.9M	-21.43M	-40.74M	-40.14M	-33.81M
Net Interest Income+	-807K	-991K	-1.48M	-553K	319.93K	55.01K	4.35K	-381K	-1.3M	-2.16M
Interest Income	9.08K	212.3K	700.9K	871.88K	353.49K	55.01K	4.35K	935.18K	2.9M	2.52M
Interest Expense	816.49K	1.2M	2.18M	1.43M	33.56K	0	0	1.32M	4.21M	4.67M
Other Income/Expense	-2.69M	-259.65K	0	0	8.13M	55.01K	4.35K	-381.34K	-1.3M	-2.16M
Pretax Income+	-29.19M	-40.67M	-53.45M	-3.84M	-7.38M	-14.85M	-21.43M	-42.05M	-44.35M	-38.48M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-1.11M	0	-2.59M	-2.78M	-381.51K	0	-4.52M	-1.2M	-1.41M	-869.17K
Effective Tax Rate %	0.96%	0.95%	0.95%	10.65%	0.95%	1%	0.79%	0.97%	0.97%	0.98%
Net Income+	-28.08M	-38.82M	-50.86M	-40.87M	-7M	-14.85M	-16.92M	-40.85M	-42.94M	-37.61M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.3%	-0.38%	-0.31%	0.2%	0.83%	-1.12%	-0.14%	-1.41%	-0.05%	0.12%
Net Income (Continuing)	-28.08M	-38.82M	-50.86M	-3.84M	-7M	-14.85M	-16.92M	-40.85M	-42.94M	-37.61M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-20.02	-26.90	-33.47	-10.25	-1.44	-0.89	-0.66	-1.43	-1.39	-1.03
EPS Growth %	-0.24%	-0.34%	-0.24%	0.69%	0.86%	0.38%	0.26%	-1.17%	0.03%	0.26%
EPS (Basic)	-20.02	-26.90	-33.47	-26.16	-1.44	-0.89	-0.66	-1.43	-1.39	-1.03
Diluted Shares Outstanding	1.4M	1.44M	1.52M	3.99M	4.87M	16.75M	25.6M	28.6M	30.95M	36.45M
Basic Shares Outstanding	1.4M	1.44M	1.52M	166.87K	4.87M	16.75M	25.6M	28.6M	30.95M	36.45M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	131.27M	107.35M	89.05M	35.65M	14.47M	30.34M	66.84M	76.48M	59.06M	45.05M
Cash & Short-Term Investments	130.19M	106.4M	88.07M	34.65M	12.16M	28.84M	65.24M	73.82M	56.56M	41.69M
Cash Only	130.19M	106.4M	88.07M	34.65M	12.16M	28.84M	65.24M	73.82M	56.56M	41.69M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	2.66M	2.49M	3.36M
Total Non-Current Assets+	2.82M	3.56M	3.57M	569.82K	21.05K	553.15K	357.7K	527.53K	335K	304.21K
Property, Plant & Equipment	2.77M	3.42M	3.42M	426.95K	21.05K	553.15K	357.7K	527.53K	335K	304.21K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	51.92K	46.8K	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	55.16K	90.95K	96.06K	142.87K	0	0	0	0	0	0
Total Assets+	134.09M	110.91M	92.62M	36.22M	14.49M	30.89M	67.2M	77.01M	59.39M	45.36M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	6.87%	-0.17%	-0.16%	-0.61%	-0.6%	1.13%	1.18%	0.15%	-0.23%	-0.24%
Total Current Liabilities+	8.59M	6.68M	12.87M	6.38M	2.79M	3.27M	3.76M	9.82M	13.63M	17.09M
Accounts Payable	2.58M	3.47M	4.37M	399.45K	1.2M	1.42M	1.31M	1.22M	6.98M	1.68M
Days Payables Outstanding	17.76K	12.65K	8.72K	2.11K	4.44K	-	-	-	44.46K	10.29K
Short-Term Debt	2.27M	0	3.08M	0	0	0	0	0	4.17M	12.5M
Deferred Revenue (Current)	34.39K	6.84K	25K	0	0	0	0	0	0	0
Other Current Liabilities	2.19M	1.87M	1.91M	5.62M	498.19K	1.31M	729.39K	0	1.29M	663.4K
Current Ratio	15.28x	16.06x	6.92x	5.59x	5.18x	9.28x	17.80x	7.79x	4.33x	2.64x
Quick Ratio	15.28x	16.06x	6.92x	5.59x	5.18x	9.28x	17.80x	7.79x	4.33x	2.64x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3.03M	14.95M	17.38M	321.23K	0	490.35K	231.43K	23.18M	19.63M	9.27M
Long-Term Debt	3.03M	14.95M	17.38M	30K	0	0	0	23.02M	19.51M	9.2M
Capital Lease Obligations	0	0	0	0	0	490.35K	231.43K	164.01K	122.97K	61.85K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	291.23K	0	0	0	0	0	0
Total Liabilities	11.62M	21.64M	30.25M	6.38M	2.79M	3.76M	3.99M	33.01M	33.26M	26.35M
Total Debt+	5.3M	14.95M	20.46M	30K	0	610.26K	490.35K	23.47M	23.85M	21.83M
Net Debt	-124.89M	-91.45M	-67.61M	-34.62M	-12.16M	-28.23M	-64.75M	-50.35M	-32.71M	-19.86M
Debt / Equity	0.04x	0.17x	0.33x	0.00x	-	0.02x	0.01x	0.53x	0.91x	1.15x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-32.45x	-32.82x	-23.84x	-30.24x	-462.15x	-	-	-31.64x	-10.23x	-7.77x
Total Equity+	122.48M	89.28M	62.37M	29.84M	11.7M	27.13M	63.21M	44M	26.13M	19M
Equity Growth %	5.4%	-0.27%	-0.3%	-0.52%	-0.61%	1.32%	1.33%	-0.3%	-0.41%	-0.27%
Book Value per Share	87.33	61.87	41.03	7.49	2.40	1.62	2.47	1.54	0.84	0.52
Total Shareholders' Equity	122.48M	89.28M	62.37M	29.84M	11.7M	27.13M	63.21M	44M	26.13M	19M
Common Stock	9.72K	9.76K	10.4K	10.59K	1.74K	7.35K	9.39K	9.96K	10.92K	12.54K
Retained Earnings	-62.25M	-101.07M	-151.95M	-192.82M	-28.94M	-43.79M	-60.7M	-101.56M	-144.5M	-182.11M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-91.39K	-122.36K	-305.28K	-451.66K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-21.75M	-32.19M	-40.7M	-33.15M	-18.07M	-13.15M	-12.49M	-25.71M	-33.64M	-35.03M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.24%	-0.48%	-0.26%	0.19%	0.45%	0.27%	0.05%	-1.06%	-0.31%	-0.04%
Net Income	-28.08M	-38.82M	-50.86M	-40.87M	-7M	-14.85M	-16.92M	-40.85M	-42.94M	-37.61M
Depreciation & Amortization	53.12K	100.12K	182.92K	69.12K	98.41K	15.61K	5.36K	86	17.36K	21.11K
Stock-Based Compensation	2.9M	5.3M	6.4M	7.62M	3.18M	452.29K	4.11M	5.2M	7.61M	6.85M
Deferred Taxes	198.96K	268.8K	141.28K	2.82M	-381.51K	0	0	0	0	0
Other Non-Cash Items	2.12M	175.91K	363.91K	531.67K	-9.36M	160.68K	241.03K	5.47M	1.87M	1.46M
Working Capital Changes	1.26M	782.43K	3.07M	-3.43M	-4.61M	1.07M	75.82K	4.47M	-199.28K	-5.75M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-71.75K	1.42M	898.1K	-3.97M	-1.98M	217.5K	-105.82K	-90.12K	5.76M	-5.3M
Cash from Investing+	-1.3M	-687K	-189K	0	29.38M	0	0	0	0	-29K
Capital Expenditures	-1.3M	-687K	-189K	0	0	0	0	0	0	-29K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	275.49K	0	0	0	0	0
Cash from Financing+	139.52M	9.09M	22.55M	-20.27M	750K	29.83M	48.89M	34.29M	16.38M	20.19M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.4M	-219.04K	171.34K	1.51M	0	70.46K	344.13K	-568.87K	308.94K	774.09K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-23.06M	-32.88M	-40.89M	-33.15M	-18.07M	-13.15M	-12.49M	-25.71M	-33.64M	-35.06M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.18%	-0.43%	-0.24%	0.19%	0.45%	0.27%	0.05%	-1.06%	-0.31%	-0.04%
FCF per Share	-16.44	-22.78	-26.90	-8.32	-3.71	-0.79	-0.49	-0.90	-1.09	-0.96
FCF Conversion (FCF/Net Income)	0.77x	0.83x	0.80x	0.81x	2.58x	0.89x	0.74x	0.63x	0.78x	0.93x
Interest Paid	0	0	0	0	0	0	0	852.22K	3.54M	3.56M
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-59.34%	-36.67%	-67.08%	-88.64%	-33.7%	-76.48%	-37.46%	-76.21%	-122.46%	-166.65%
Debt / Equity	0.04x	0.17x	0.33x	0.00x	-	0.02x	0.01x	0.53x	0.91x	1.15x
Interest Coverage	-32.45x	-32.82x	-23.84x	-30.24x	-462.15x	-	-	-31.64x	-10.23x	-7.77x
FCF Conversion	0.77x	0.83x	0.80x	0.81x	2.58x	0.89x	0.74x	0.63x	0.78x	0.93x

Frequently Asked Questions

Growth & Financials

PDS Biotechnology Corporation (PDSB) grew revenue by 0.0% over the past year. Growth has been modest.

PDS Biotechnology Corporation (PDSB) reported a net loss of $34.9M for fiscal year 2024.

Dividend & Returns

PDS Biotechnology Corporation (PDSB) has a return on equity (ROE) of -166.7%. Negative ROE indicates the company is unprofitable.

PDS Biotechnology Corporation (PDSB) had negative free cash flow of $32.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

PDS Biotechnology Corporation (PDSB) 10-Year Financial Performance & Capital Metrics

PDSB • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$36M +15.6%
Net Income -$38M +12.4%
EPS (Diluted) -1.03 +25.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -166.65% -36.1%
ROIC -
Debt/Equity 1.15 +25.8%
Interest Coverage -7.77 +24.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 19 (bottom 19%)
✗Shares diluted 17.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM13.98%

EPS CAGR

10Y-

5Y-

3Y-

TTM28.45%

ROCE

10Y Avg-64.35%

5Y Avg-72.21%

3Y Avg-79.38%

Latest-98.12%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	53.12K	100.12K	182.92K	69.12K	98.41K	0	0	0	57.33K	59.79K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-53.12K	-100K	-183K	-69.12K	-98.41K	0	0	0	-57.33K	-59.79K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.88%	-0.83%	0.62%	-0.42%	1%	-	-	-	-0.04%
Operating Expenses+	26.5M	39.51M	51.97M	3.65M	15.41M	14.9M	21.44M	41.67M	43.05M	36.26M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	8.66M	14.69M	17.66M	14.29M	9.31M	6.98M	10.18M	12.24M	15.28M	13.7M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	17.84M	24.82M	34.31M	830.74K	6.1M	7.92M	11.25M	29.43M	27.76M	22.57M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	-163.46K	0	12.74B	0	0	0	0	1K	0
Operating Income+	-26.5M	-39.51M	-51.97M	-43.1M	-15.51M	-14.9M	-21.44M	-41.67M	-43.05M	-36.32M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-1.01%	-0.49%	-0.32%	0.17%	0.64%	0.04%	-0.44%	-0.94%	-0.03%	0.16%
EBITDA+	-26.45M	-39.41M	-51.78M	-43.03M	-15.41M	-14.89M	-21.43M	-41.67M	-42.99M	-36.26M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1.01%	-0.49%	-0.31%	0.17%	0.64%	0.03%	-0.44%	-0.94%	-0.03%	0.16%
D&A (Non-Cash Add-back)	53.12K	100.12K	182.92K	69.12K	98.41K	15.61K	5.36K	86	57.33K	59.79K
EBIT	-28.37M	-39.46M	-51.27M	-3.83M	-7.35M	-14.9M	-21.43M	-40.74M	-40.14M	-33.81M
Net Interest Income+	-807K	-991K	-1.48M	-553K	319.93K	55.01K	4.35K	-381K	-1.3M	-2.16M
Interest Income	9.08K	212.3K	700.9K	871.88K	353.49K	55.01K	4.35K	935.18K	2.9M	2.52M
Interest Expense	816.49K	1.2M	2.18M	1.43M	33.56K	0	0	1.32M	4.21M	4.67M
Other Income/Expense	-2.69M	-259.65K	0	0	8.13M	55.01K	4.35K	-381.34K	-1.3M	-2.16M
Pretax Income+	-29.19M	-40.67M	-53.45M	-3.84M	-7.38M	-14.85M	-21.43M	-42.05M	-44.35M	-38.48M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-1.11M	0	-2.59M	-2.78M	-381.51K	0	-4.52M	-1.2M	-1.41M	-869.17K
Effective Tax Rate %	0.96%	0.95%	0.95%	10.65%	0.95%	1%	0.79%	0.97%	0.97%	0.98%
Net Income+	-28.08M	-38.82M	-50.86M	-40.87M	-7M	-14.85M	-16.92M	-40.85M	-42.94M	-37.61M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.3%	-0.38%	-0.31%	0.2%	0.83%	-1.12%	-0.14%	-1.41%	-0.05%	0.12%
Net Income (Continuing)	-28.08M	-38.82M	-50.86M	-3.84M	-7M	-14.85M	-16.92M	-40.85M	-42.94M	-37.61M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-20.02	-26.90	-33.47	-10.25	-1.44	-0.89	-0.66	-1.43	-1.39	-1.03
EPS Growth %	-0.24%	-0.34%	-0.24%	0.69%	0.86%	0.38%	0.26%	-1.17%	0.03%	0.26%
EPS (Basic)	-20.02	-26.90	-33.47	-26.16	-1.44	-0.89	-0.66	-1.43	-1.39	-1.03
Diluted Shares Outstanding	1.4M	1.44M	1.52M	3.99M	4.87M	16.75M	25.6M	28.6M	30.95M	36.45M
Basic Shares Outstanding	1.4M	1.44M	1.52M	166.87K	4.87M	16.75M	25.6M	28.6M	30.95M	36.45M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	131.27M	107.35M	89.05M	35.65M	14.47M	30.34M	66.84M	76.48M	59.06M	45.05M
Cash & Short-Term Investments	130.19M	106.4M	88.07M	34.65M	12.16M	28.84M	65.24M	73.82M	56.56M	41.69M
Cash Only	130.19M	106.4M	88.07M	34.65M	12.16M	28.84M	65.24M	73.82M	56.56M	41.69M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	2.66M	2.49M	3.36M
Total Non-Current Assets+	2.82M	3.56M	3.57M	569.82K	21.05K	553.15K	357.7K	527.53K	335K	304.21K
Property, Plant & Equipment	2.77M	3.42M	3.42M	426.95K	21.05K	553.15K	357.7K	527.53K	335K	304.21K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	51.92K	46.8K	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	55.16K	90.95K	96.06K	142.87K	0	0	0	0	0	0
Total Assets+	134.09M	110.91M	92.62M	36.22M	14.49M	30.89M	67.2M	77.01M	59.39M	45.36M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	6.87%	-0.17%	-0.16%	-0.61%	-0.6%	1.13%	1.18%	0.15%	-0.23%	-0.24%
Total Current Liabilities+	8.59M	6.68M	12.87M	6.38M	2.79M	3.27M	3.76M	9.82M	13.63M	17.09M
Accounts Payable	2.58M	3.47M	4.37M	399.45K	1.2M	1.42M	1.31M	1.22M	6.98M	1.68M
Days Payables Outstanding	17.76K	12.65K	8.72K	2.11K	4.44K	-	-	-	44.46K	10.29K
Short-Term Debt	2.27M	0	3.08M	0	0	0	0	0	4.17M	12.5M
Deferred Revenue (Current)	34.39K	6.84K	25K	0	0	0	0	0	0	0
Other Current Liabilities	2.19M	1.87M	1.91M	5.62M	498.19K	1.31M	729.39K	0	1.29M	663.4K
Current Ratio	15.28x	16.06x	6.92x	5.59x	5.18x	9.28x	17.80x	7.79x	4.33x	2.64x
Quick Ratio	15.28x	16.06x	6.92x	5.59x	5.18x	9.28x	17.80x	7.79x	4.33x	2.64x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3.03M	14.95M	17.38M	321.23K	0	490.35K	231.43K	23.18M	19.63M	9.27M
Long-Term Debt	3.03M	14.95M	17.38M	30K	0	0	0	23.02M	19.51M	9.2M
Capital Lease Obligations	0	0	0	0	0	490.35K	231.43K	164.01K	122.97K	61.85K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	291.23K	0	0	0	0	0	0
Total Liabilities	11.62M	21.64M	30.25M	6.38M	2.79M	3.76M	3.99M	33.01M	33.26M	26.35M
Total Debt+	5.3M	14.95M	20.46M	30K	0	610.26K	490.35K	23.47M	23.85M	21.83M
Net Debt	-124.89M	-91.45M	-67.61M	-34.62M	-12.16M	-28.23M	-64.75M	-50.35M	-32.71M	-19.86M
Debt / Equity	0.04x	0.17x	0.33x	0.00x	-	0.02x	0.01x	0.53x	0.91x	1.15x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-32.45x	-32.82x	-23.84x	-30.24x	-462.15x	-	-	-31.64x	-10.23x	-7.77x
Total Equity+	122.48M	89.28M	62.37M	29.84M	11.7M	27.13M	63.21M	44M	26.13M	19M
Equity Growth %	5.4%	-0.27%	-0.3%	-0.52%	-0.61%	1.32%	1.33%	-0.3%	-0.41%	-0.27%
Book Value per Share	87.33	61.87	41.03	7.49	2.40	1.62	2.47	1.54	0.84	0.52
Total Shareholders' Equity	122.48M	89.28M	62.37M	29.84M	11.7M	27.13M	63.21M	44M	26.13M	19M
Common Stock	9.72K	9.76K	10.4K	10.59K	1.74K	7.35K	9.39K	9.96K	10.92K	12.54K
Retained Earnings	-62.25M	-101.07M	-151.95M	-192.82M	-28.94M	-43.79M	-60.7M	-101.56M	-144.5M	-182.11M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-91.39K	-122.36K	-305.28K	-451.66K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-21.75M	-32.19M	-40.7M	-33.15M	-18.07M	-13.15M	-12.49M	-25.71M	-33.64M	-35.03M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.24%	-0.48%	-0.26%	0.19%	0.45%	0.27%	0.05%	-1.06%	-0.31%	-0.04%
Net Income	-28.08M	-38.82M	-50.86M	-40.87M	-7M	-14.85M	-16.92M	-40.85M	-42.94M	-37.61M
Depreciation & Amortization	53.12K	100.12K	182.92K	69.12K	98.41K	15.61K	5.36K	86	17.36K	21.11K
Stock-Based Compensation	2.9M	5.3M	6.4M	7.62M	3.18M	452.29K	4.11M	5.2M	7.61M	6.85M
Deferred Taxes	198.96K	268.8K	141.28K	2.82M	-381.51K	0	0	0	0	0
Other Non-Cash Items	2.12M	175.91K	363.91K	531.67K	-9.36M	160.68K	241.03K	5.47M	1.87M	1.46M
Working Capital Changes	1.26M	782.43K	3.07M	-3.43M	-4.61M	1.07M	75.82K	4.47M	-199.28K	-5.75M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-71.75K	1.42M	898.1K	-3.97M	-1.98M	217.5K	-105.82K	-90.12K	5.76M	-5.3M
Cash from Investing+	-1.3M	-687K	-189K	0	29.38M	0	0	0	0	-29K
Capital Expenditures	-1.3M	-687K	-189K	0	0	0	0	0	0	-29K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	275.49K	0	0	0	0	0
Cash from Financing+	139.52M	9.09M	22.55M	-20.27M	750K	29.83M	48.89M	34.29M	16.38M	20.19M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.4M	-219.04K	171.34K	1.51M	0	70.46K	344.13K	-568.87K	308.94K	774.09K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-23.06M	-32.88M	-40.89M	-33.15M	-18.07M	-13.15M	-12.49M	-25.71M	-33.64M	-35.06M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.18%	-0.43%	-0.24%	0.19%	0.45%	0.27%	0.05%	-1.06%	-0.31%	-0.04%
FCF per Share	-16.44	-22.78	-26.90	-8.32	-3.71	-0.79	-0.49	-0.90	-1.09	-0.96
FCF Conversion (FCF/Net Income)	0.77x	0.83x	0.80x	0.81x	2.58x	0.89x	0.74x	0.63x	0.78x	0.93x
Interest Paid	0	0	0	0	0	0	0	852.22K	3.54M	3.56M
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-59.34%	-36.67%	-67.08%	-88.64%	-33.7%	-76.48%	-37.46%	-76.21%	-122.46%	-166.65%
Debt / Equity	0.04x	0.17x	0.33x	0.00x	-	0.02x	0.01x	0.53x	0.91x	1.15x
Interest Coverage	-32.45x	-32.82x	-23.84x	-30.24x	-462.15x	-	-	-31.64x	-10.23x	-7.77x
FCF Conversion	0.77x	0.83x	0.80x	0.81x	2.58x	0.89x	0.74x	0.63x	0.78x	0.93x

Frequently Asked Questions

Growth & Financials

PDS Biotechnology Corporation (PDSB) grew revenue by 0.0% over the past year. Growth has been modest.

PDS Biotechnology Corporation (PDSB) reported a net loss of $34.9M for fiscal year 2024.

Dividend & Returns

PDS Biotechnology Corporation (PDSB) has a return on equity (ROE) of -166.7%. Negative ROE indicates the company is unprofitable.

PDS Biotechnology Corporation (PDSB) had negative free cash flow of $32.3M in fiscal year 2024, likely due to heavy capital investments.